On August 9, 2022 BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB,OTCQB: BVAXF) ("BioVaxys" or the "Company") reported that it has extended the expiry date of 4,483,689 share purchase warrants with an exercise price of $0.50 and expiry date of August 26, 2022 and 1,477,291 share purchase warrants with an exercise price of $0.50 and an expiry date of September 3, 2022 (the "Warrants") that were issued pursuant to private placements that closed on August 26, 2020 and September 3, 2020, respectively (Press release, BioVaxys Technology, AUG 9, 2022, View Source [SID1234618035]). The Warrants amended expiry date is January 26, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!